The shorter 6-month regimen could save enough to supply 400,000 people with almost a year's worth of treatment.
The findings suggest the drug could be part of a shorter and simpler tuberculosis treatment regimen.
A study today in BMC Medicine highlights the toll that the COVID-19 pandemic has taken on the diagnosis of tuberculosis (TB) in high-burden countries, particularly in vulnerable populations.
A clinical trial conducted in seven countries found that two shortened, bedaquiline-containing regimens had superior efficacy in treating rifampicin-resistant tuberculosis (TB) compared with a 9-month injectable-containing regimen, with fewer cases of hearing loss, investigators reported today in The Lancet.
WHO officials say the COVID-19 pandemic's impact on essential TB services has reversed years of progress.
A systematic review and meta-analysis today in Vaccine finds no link between COVID-19 vaccines and infertility in men or women.
Researchers at a Rome hospital analyzed 29 studies from China, Israel, Italy, Russia, Turkey, Canada, and the United States until Jun 8, 2022. Of the studies, 13.8% were deemed of poor quality, 58.6% were of moderate quality, and 27.6% were of good quality.
A relatively simple 6-month regimen cured 90% or more of patients who have MDR-TB.
A randomized clinical trial in Niger found that mass distribution of azithromycin to preschool-aged children was no more effective at reducing incidence of trachoma than placebo, researchers reported today in JAMA Network Open.
The process generates a list of antibiotics to which the infection is susceptible.
A survey of tuberculosis (TB) treatment centers in Europe found the availability of drug susceptibility testing (DST) for new and repurposed TB drugs in Europe is severely limited, drugs and regimens for drug-resistant TB are limited, and treatment costs for drug-resistant TB are very high, according to a study published this week in Clinical Microbiology and Infection.
